Procter & Gamble Health Ltd
NSE: PGHL BSE: 500126
₹5305
(0.04)%
Mon, 02 Feb 2026, 00:47 am
Market Cap87.98B
PE Ratio28.70
Dividend2.36
Health Technology
Pharmaceuticals: Major
24.5Kproctergamble health ltd History
1967
- Company incorporated on 26 April as private limited company.
1974
- 12,782 shares issued without payment in proportion 1:3.
1977
- 2,500 bonus shares issued in proportion 1:3.
1979
- 50,000 bonus shares issued in proportion 1:2.
1981
- Company converted to public limited company on 29 June.
- Non-resident equity holding reduced from 60% to 51%.
- Shares subdivided on 29 June.
- Issued 5,02,500 shares to Chemitra GmbH and 47,500 as rights to residents.
- Offered 7,02,067 shares for public subscription.
1985
- Privately placed 1,00,000 15% non-convertible debentures with Army Group Insurance Fund.
- Privately placed 2,00,000 15% non-convertible debentures with UTI.
1986
- Introduced drugs including Praziquantel, Septopal Beads, and anti-cancer drugs.
- 16,50,000 bonus equity shares issued in proportion 3:5.
1987
- Company acquired bulk drug unit at Indore manufacturing chloroquine phosphate.
- Company acquired significant shareholding in Suneeta Laboratories, Indore.
- 15,40,000 shares issued at premium of Rs 10 per share on rights and preferential basis.
1989
- Company launched diagnostics project.
- Company launched pharmaceutical formulation division for BDH trademark.
- Company offered 5,50,000 14% secured redeemable non-convertible debentures on rights basis.
1990
- Company name changed to BDH Pharmaceuticals Ltd.
- Company sold Indore plant to BDH Pharma for Rs 200 lakhs.
1991
- 29,70,000 bonus equity shares issued in proportion 1:2.
1992
- Company offered 5,55,428 zero interest fully convertible debentures on rights basis.
- Issued 27,772 zero interest debentures to employees.
- Issued 2,49,500 zero interest debentures to Emedia Export Company GmbH and 1,39,300 to Chemilia GmbH.
1993
- Company issued 30,91,224 equity shares to Merck AG to increase stake to 51%.
- Poor performance attributed to Indore plant sale and reduced Guaiazulene offtake to Japan.
1997
- Company redeemed 14% NCDs (Series II) aggregating Rs 55 million.
1998
- EMI operated five divisions: pharma, reagents, bulk drugs, diagnostics, pigments.
- E Merck India assigned Polybion brand to small scale manufacturer.
- Company redeemed one-third of 16.5% NCDs held by UTI.
1999
- E Merck decided against joint venture for OTC business.
- E Merck India positioned as largest vitamins market player.
- E Merck India planned introduction of premium laboratory chemicals.
2000
- E. Merck and Kopran entered co-marketing arrangement for atorvastatin.
2002
- Prof. Thomas Schereckenbach appointed as Additional Director.
- Mr. K. J. Mallya appointed as Company Secretary and Compliance Officer.
2004
- Merck signed Deed of Assignment with Biochem Pharmaceuticals.
2007
- Mr. K Shivkumar appointed as Additional Director.
2009
- Mr. Ralph Antonius Zaat appointed as Director replacing Dr. Hans Hermansson.
2010
- Company recommended final dividend of Rs. 20 per share.
- Merck KGaA and sanofi-aventis signed agreement for novel cancer combinations.
- Merck KGaA donation program supported Schistosomiasis control in Africa.
- FDA approved Egrifta for HIV-infected patients with lipodystrophy.
2011
- Merck KGaA intended to name Matthias Zachert to Executive Board.
- Merck appointed Frederic Wohlwend as CIO.
- Merck strengthened research cooperation with Israel.
- Merck received European approval for three pre-filled pen injectors for fertility treatment.
2012
- Merck donated 100 millionth tablet to treat Schistosomiasis.
- Standard & Poor’s raised Merck’s long-term credit rating to A-.
- Merck advanced to eighth place in Access to Medicine Index.
- Jon Baumhauer awarded Luther Rose.
- Merck Serono announced final efficiency program for Switzerland.
2013
- Merck invested in research partnerships in Israel.
2014
- Merck Serono formed global Oncology Partnership and Education Network (OPEN).
2015
- Merck Ltd moved corporate office to Godrej One, Mumbai.
- Merck acquired Ormet Circuits.
- Merck helped refugees in Lebanon.
- Merck and Pfizer advanced Phase III trials for Avelumab.
- Merck and Pfizer received positive EMA opinion for Avelumab orphan drug designation in Merkel Cell Carcinoma.
2016
- Merck expanded distribution agreement with Roche.
- Merck won R&D 100 Award for top invention.
- Merck outlined future strategic roadmap targeting 2018.
- Merck presented its first Russian Literary Prize.
2018
- P&G acquired Consumer Health Business of Merck KGaA, Darmstadt, Germany.
2019
- P&G Health launched PANACHE platform for medical students.
2020
- P&G Health partnered with PHFI for Digital Health Project at Goa under SEHAT CSR Program.
2021
- P&G Health partnered with Tata Trusts to advance nutritional status of women and children in Andhra Pradesh.
- P&G Health commemorated Iron Deficiency Day with GUINNESS WORLD RECORDS achievement.
2022
- P&G Health launched Na Na Anemia Bus Yatra across 20 cities for Iron Deficiency Anemia awareness.
- P&G Health partnered with Lakshya and Recycle India Foundation for sustainable pharmacy waste management.
- P&G Health brought global nerve care experts together for Peripheral Neuropathy awareness.
- P&G Health partnered with Apnalaya to improve maternal and newborn health in Mumbai slums.
2023
- P&G Health partnered with Indian Academy of Pediatrics for Sankalp: Sampoorna Swasthya school healthcare initiative.
- P&G Health launched Mobile Healthcare Unit with HelpAge India in Guwahati.
- P&G Health collaborated with Indian Medical Association to launch VitaM.I.N.D.S conclave.
- Polybion celebrated World Health Day and launched Pragati Utsav for Vitamin B Deficiency awareness.
2024
- P&G Health and HelpAge India collaborated to improve healthcare access in Palghar.
- P&G Health's Nasivion entered Asia Book of Records.
- P&G Health achieved GUINNESS WORLD RECORDS title for largest online photo album of people wearing pin badges.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800